Merck KGaA agreed on June 25, 2026, to acquire Bio-Techne Corporation for $73 per share in an all-cash deal, valuing the Minneapolis-based company at $11.3 billion in enterprise value (€9.9 billion), according to Merck KGaA's announcement and Reuters reporting.

This is Merck KGaA's largest acquisition in over a decade. For scale, the German company's last major move was buying Sigma-Aldrich in 2015 for roughly $17 billion—a deal that reshaped its Life Science division. That division sells the reagents, instruments, and consumables that pharmaceutical and academic labs need to discover and develop new drugs. It competes directly with Thermo Fisher, Danaher, and—through Sigma-Aldrich—Merck's own portfolio.

Bio-Techne specializes in proteins, antibodies, and immunoassays—the laboratory tools that drug researchers rely on daily. Its brands, including R&D Systems and Tocris, are standard in academic and biotech research labs worldwide. These products generate steady, high-margin revenue with modest capital requirements, which is why strategic buyers in this sector pay premium prices for them. Merck is acquiring durable recurring revenue and a hard-to-replicate catalogue of research reagents.

The immediate question for fixed-income investors: how will Merck manage the balance sheet? At $11.3 billion, this all-cash transaction avoids diluting Merck KGaA shareholders but adds debt. The company's ability to reduce that debt post-closing will shape its credit profile in the near term. The actual financial multiple—enterprise value divided by EBITDA or revenue—hasn't been published yet, but the all-cash structure tells you this was a premium acquisition.

The strategic logic is solid. Life-science tools demand tracks closely with pharmaceutical and biotech research spending, which has held up reasonably well even as biotech funding slowed from its 2021 peak. Adding Bio-Techne's protein and assay franchises gives Merck deeper catalogue strength, particularly with customers running early-stage discovery work. In research labs, switching to a competitor's tools is costly once teams have built workflows around a trusted brand—that switching cost is valuable to the acquirer.

Before closing, the deal needs US and EU regulatory approval and Bio-Techne shareholder sign-off. All-cash acquisitions this size typically draw antitrust scrutiny. The key question for regulators will be whether Merck's existing Life Science products and Bio-Techne's offerings overlap enough to warrant conditions or divestitures. No closing date was announced as of June 25, 2026.